Sign in
Taking peopleNo phase

Swiss Pilot Screening Study for Unruptured Intracranial Aneurysms to Prevent Subarachnoid Hemorrhage in Smokers

Key facts

Who runs it
Insel Gruppe AG, University Hospital Bern
Where
Switzerland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
200 people, planned
Started
28 Jul 2023
Expected to end
31 Jan 2028
Type of study
Interventional
Treatments tested
  • 3T-MRI scan
Record updated
16 November 2026

Who can take part

Age
30 years to 60 years
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Women and men
  • Age 30-60 years
  • Active cigarette smoking with a cumulative exposure ≥ 10 pack-years
  • Smoking cessation no longer than 6 months ago (<6 months

Who cannot take part

  • History of subarachnoid hemorrhage
  • History of polycystic kidney disease, Ehlers-Danlos syndrome, Marfan's syndrome, fibromuscular dysplasia, Moya-Moya disease, or Loeys-Dietz syndrome, history of ≥2 family members with SAH/UIA
  • Contraindications to undergo MRI
  • Patients with known UIA
  • Pregnancy

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Unruptured intracranial aneurysm or aneurysmal subarachnoid hemorrhage

This trial is currently available in Switzerland.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Unruptured intracranial aneurysms (UIAs) are potentially life-threatening vascular lesions that may rupture and cause aneurysmal subarachnoid hemorrhage (SAH), a condition associated with substantial morbidity and mortality. The prevalence of UIAs in the general population is approximately 3.2%. Current guidelines recommend screening primarily for individuals with a strong family history of UIA/SAH or autosomal dominant polycystic kidney disease (ADPKD). However, these groups account for only a minority of patients with UIAs.

Read full original descriptionShow less

Smoking is a major modifiable risk factor for UIA formation and rupture. Preliminary studies suggest that UIA prevalence may be substantially higher among smokers than in the general population, but prospective data are limited, particularly in men.

This prospective screening study aims to determine the prevalence of UIAs in active and recent smokers aged 30-60 years with a smoking history of at least 10 pack-years. We hypothesize that UIA prevalence in this population is significantly higher than in the general population and may approach that of established high-risk groups.

Participants will undergo non-contrast 3T magnetic resonance angiography (time-of-flight sequence). Baseline demographic and clinical characteristics, smoking habits, nicotine dependence, and quality of life will be assessed using REDCap questionnaires. Imaging findings will be communicated to participants, and those with detected aneurysms or relevant incidental findings will be referred for standard clinical evaluation. At 30 (±14) days after MRI, smoking habits, nicotine dependence, quality of life, and consequences of screening will be reassessed. The study will also evaluate the clinical implications and costs of screening.

The group in the trial

  • screening for unruptured intracranial aneurysmsTreatment being tested

    3T-MRI examination for Unruptured intracranial aneurysms

    Treatment: 3T-MRI scan

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT07938775, who can take part
Record updated
16 November 2026